Watson Pharmaceuticals, Inc. entered an agreement to acquire exclusive U.S. rights to Columbia Laboratories, Inc.’s bioadhesive progesterone gel products currently marketed as Crinone and Prochieve for the indications of infertility and secondary amenorrhea. The two companies will collaborate for the ongoing Phase III development program for a new indication for these products for the prevention of preterm birth, as well as a global development program for second-generation products for th...